trending Market Intelligence /marketintelligence/en/news-insights/trending/x53h6rjdiRTZfc0CAbgcRQ2 content esgSubNav
In This List

Oncology Venture nabs global rights to drug response prediction technology

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Oncology Venture nabs global rights to drug response prediction technology

Oncology Venture Sweden AB secured global exclusive development rights to Medical Prognosis Institute A/S' drug response prediction technology for a period of three years.

Oncology Venture will issue purchase warrants in exchange for the technology to develop new treatments. The warrants will be exercisable at 10 Swedish kronor for every share issued until Dec. 31, 2019.

Furthermore, Medical Prognosis will receive an ownership stake in Oncology Venture's special purpose vehicles instead of payments and earnings from the sale of the drugs developed by the technology.

As of Dec. 29, US$1 was equivalent to 9.12 Swedish kronor.